webinars
THURSDAY, APRIL 2nd | 1:30PM EST Biomarkers can move a program forward fast. Or slow it down with rework. Biomarkers shape decisions from discovery through late-stage clinical trials. But the wrong assay plan can waste time, budget and samples. In this KCAS Bio roundtable, we share practical ways to align…
At KCAS Bio, we supported a therapeutic monoclonal antibody for advanced solid tumors from non-human primate (NHP) toxicology through first-in-human (FIH) dose escalation into phase 2 expansion. This project combined receptor occupancy assays (ROA) by flow cytometry for cell-surface binding on monocytes, immunophenotyping (IPT) for activation markers, and…
In the newest episode of “The Weekly Bioanalysis” podcast, our hosts, John and Dom welcome Scott Weir (Director, Institute for Advancing Medical Innovation at KU Medical Center) for a practical, behind-the-scenes look at how drug discovery and development can be executed in an academic setting—and what it takes to translate…
Evolving CAR Therapies and the Growing Need for Robust PK/PD Monitoring Chimeric Antigen Receptor (CAR) based therapies are a growing and continuing focus in oncology and autoimmune therapeutic development. They utilize either self (autologous) or donor-derived (allogenic) T cells that are genetically engineered to target and kill cancerous or autoreactive…
Developing a robust Pharmacokinetic (PK) assay for biotherapeutics often presents unforeseen biological hurdles. Occasionally, a traditional Ligand Binding Assay (LBA) may yield inconsistent data. In this particular case, the LBA assay was not reliably detecting drug in the matrix, potentially indicating some matrix stability issue during method development. In addition,…
News
KCAS Bio is proud to announce that its EU site (Lyon, France) has successfully renewed its Statement of Compliance with Good Laboratory Practices (GLP), confirming its ability to deliver GLP-grade bioanalytical methods in support of preclinical studies. Our GLP test facility was granted a Level of compliance “A”, reinforcing KCAS Bio’s capability to…
In episode #29 of “The Conversational Flow” podcast, our hosts, Brian and Adam, are joined by guests from Accelerating Cancer Immunotherapy Research (ACIR), a nonprofit dedicated to sharing important advances in cancer immunotherapy with the scientific community and the public. Ute Burkhardt discusses her background in cancer vaccines and neoantigen-driven…
May 31
- June 4
KCAS Bio will be attending the 74th Conference on Mass Spectrometry and Allied Topics (ASMS) in San Diego, California from May 31 – June 4, 2026. This event is a cornerstone in the field of mass spectrometry, bringing together experts, innovators, and visionaries to share advancements and explore the future…
May 11
- May 15
KCAS Bio is exhibiting at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 11th-15th, 2026, in Boston, MA. This event serves as a global hub for scientific discovery and collaboration, bringing together leaders and innovators in the field of gene and cell…
May 11
- May 14
KCAS Bio will be exhibiting at the American Association of Pharmaceutical Scientists National Biotechnology Conference (AAPS NBC), taking place from May 11th to May 14th, 2026, in San Diego, California. Visit KCAS Bio at Booth #302 to engage with our experts, explore our cutting-edge bioanalysis solutions, and learn how we…
Reliable immune profiling across global studies depends on methods that perform consistently, regardless of where they are run. We address this question in the white paper entitled “Cross-Site Validation of a 15-Color Spectral Cytometry Panel for Leukocyte Profiling,” documenting a global collaboration between KCAS Bio and its strategic partner,…
Posters & Papers
Discover in this white paper a global collaboration between KCAS Bio and its strategic partner, Crux Biolabs, to harmonize and validate a standardized 15-color spectral flow cytometry panel for pan-leukocyte profiling across multiple sites. If you have any questions about these services or any others offered by…